İnsan çevirisi örneklerinden çeviri yapmayı öğrenmeye çalışıyor.
Profesyonel çevirmenler, işletmeler, web sayfaları ve erişimin serbest olduğu çeviri havuzlarından.
cohort
cohorte
Son Güncelleme: 2017-04-26
Kullanım Sıklığı: 37
Kalite:
cohort eff
efecto de generación
Son Güncelleme: 2014-12-09
Kullanım Sıklığı: 1
Kalite:
Uyarı: Bu hizalama yanlış olabilir..
Böyle düşünüyorsanız lütfen silin.
cohort 2 – regimen b: 1000 mg (2 x 500 mg) firibastat mr formulation qd for 7 days capsule in the fasted state.
cohorte 2 – régimen b: 1000 mg (2 x 500 mg) formulación qd de cápsula de lm de firibastat durante 7 días en ayunas.
cohort 2 with previously treated patients (n = 56): patients who had been previously treated for their brain metastases and had progressed following this treatment.
cohorte 2 con pacientes previamente tratados (n = 56): pacientes que habían sido previamente tratados para sus metastásis cerebrales y habían progresado tras este tratamiento.
in cohort 2 (patients with surgically salvageable disease whose planned surgery was associated with severe morbidity), 209 of the 228 evaluable patients treated with xgeva had not undergone surgery by month 6.
en la cohorte 2 (pacientes con enfermedad quirúrgicamente salvable cuya cirugía planeada estaba asociada a morbilidad grave), 209 de los 228 pacientes evaluables tratados con xgeva no se sometieron a una cirugía hasta los 6 meses.
cohort 2 (n=3) received asfotase alfa 3 mg/kg intravenously the first week followed by 3 doses at 2 mg/kg subcutaneous at weekly intervals from weeks 2 to 4.
la cohorte 2 (n = 3) recibió 3 mg/kg de asfotasa alfa por vía intravenosa la primera semana y a continuación 3 dosis de 2 mg/kg por vía subcutánea a intervalos semanales desde la semana 2 a la 4.
gemini ii contained two cohorts of patients that received vedolizumab at weeks 0 and 2: cohort 1 patients were randomised to receive either vedolizumab 300 mg or placebo in a double-blind fashion, and cohort 2 patients were treated with open-label vedolizumab 300 mg.
el ensayo gemini ii incluía dos cohortes de pacientes que recibieron vedolizumab en las semanas 0 y 2: en la cohorte 1, los pacientes fueron aleatorizados a recibir 300 mg de vedolizumab o placebo en un diseño doble ciego, y en la cohorte 2, los pacientes fueron tratados con 300 mg de vedolizumab en régimen abierto.
after the 2 mg/kg weekly subcutaneous administration in cohort 2 the mean (sd) auc was 138595 (6958) and 136109 (41875) following the first and the third dose, respectively.
tras la administración subcutánea semanal de 2 mg/kg en la cohorte 2, el auc media (de) fue de 138595 (6958) y 136109 (41875) tras la primera y la tercera dosis, respectivamente.